BioSpace News Archive

Rising geriatric population, growing prevalence of neurological disorders such as Parkinson’s disease, epilepsy, and dystonia, and continuous advancements in neurosurgical technologies are among the key factors expected to drive market revenue growth.

Growing geriatric population worldwide, rising cases of oral disorders, and increasing demand for advanced dental imaging solutions are among the key factors expected to drive market revenue growth during the forecast period.

Onera Health , a leader in transforming sleep medicine and remote monitoring, today announced that it was awarded a 2021 Leadership Award by Frost & Sullivan in the category of European Sleep Diagnostics Technology Innovation for its unique and innovative solutions.

BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces positive early data from the ongoing clinical study of its novel anti-FcyRIIB antibody BI-1206 in combination with anti-PD-1 therapy pembrolizumab for the treatment of patients with solid tumors.

Natus Medical Incorporated announced the appointment of Thomas J. Sullivan as President & Chief Executive Officer effective December 27, 2021 and a focus on long-term growth.

Pulmatrix, Inc. announced that it has closed its previously announced registered direct offering with certain institutional investors for the issuance and sale of an aggregate of 6,745.008 shares of convertible preferred stock and warrants to purchase up to an aggregate of 5,620,834 shares of common stock for gross proceeds of $6.75 million, prior to deducting placement agent’s fees and other offering expenses.

Arrowhead Pharmaceuticals, Inc. announced that as an inducement to entering into employment with the Company, on December 14, 2021, the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 24 new employees under Rule 5635 of the NASDAQ Listing Rules.

argenx SE (Euronext & Nasdaq: ARGX), today announced that the U.S. Food and Drug Administration (FDA) has approved VYVGART™ (efgartigimod alfa-fcab) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

The enhanced knowledge that certain diseases are caused by the inheritance of single functionally defective gene has laid the idea of gene therapy.

Company poised to transform drug development and personalised healthcare in 2022, following series of key pharma partnerships leveraging its leading genomics platform and global real-world data access network.